On the 12 th -16 th of March, in Astana, within the framework of the memorandum signed between the Republican Center for Health Development and SANTO, with the support of Polpharma, an expert training was held on the topic: “Methods and application of medical technology assessment within the framework of the drug provision financing system” and a round table on the topic : “Medical technology assessment in the strategic management and regulation of health care: making decisions at the national and regional level within the framework of the drug provision financing system”. The trainer and the main speaker was Dr.Krzysztof Landa, an international consultant for Dentos, a consultant on strategic medical technologies in the international company Dentos Business Dervices EMEA, formerly Vice Minister of Health of Poland for the period 2015-2017.

The training was attended by experts in the field of medical technology assessment and rational drug provision in the Republican Center for Health Development and other organizations in the
healthcare system of the Republic of Kazakhstan. Medical technology assessment (MTA) is an integrated interdisciplinary approach for analyzing health policy, based on the long-term consequences of applying existing or new technologies for medical care. The medical technology assessment is conducted to justify decisions and form health policy, based on objective information. With this approach, the following medical technologies are assessed: medicines, medical equipment, procedures, and organization structures of the health care system.

The participants of the training studied the international experience and expertise in the application of medical technology assessment methods in the financing of drug provision in the health insurance system, guidelines in the field of evidence-based medicine, biostatistics, evaluation of data on the cost of medical technology, financing of a basic benefits package, including drug provision, prospects for introducing the price formation by the ratio of value to the cost. The health care system in Kazakhstan is in the process of reforming and introducing the system of compulsory social health insurance, therefore the detailed study of advanced international experience and the best practices in this given area is of great practical interest.

During the round table on the 15 th -16 th of March, experts discussed such issues as the role of the medical technology assessment (MTA) for making decisions in the formation of drug provision financing lists and in the formation of a basic benefits package in compulsory health insurance; basic and additional health insurance packages, priority setting - operating models of MTA of the agency: light touch or heavy touch. In addition, the participants discussed the national management on MTA and the regulation of financing of drug provision in the European Union, using the example of Poland.

During the opening of the round table, Jiri Urbanec, CEO of SANTO, said: “The organization of this meeting and training held this week with Dr. Landa is a very important step towards the
introduction of international practices and standards for the successful development of the healthcare system. This is very important now, when Kazakhstan is on the verge of introducing
a compulsory health insurance system. The participants of the training and round table got acquainted with the experience of the European Union in using the expert assessment of medical technologies in making decisions on the financing of drug provision. After all, our future, the future of Kazakhstan, is dependent on this knowledge and new experience, and, thus, more patients can receive treatment.”


ABOUT SANTO:

SANTO Member of Polpharma Group is the trademark of Chimpharm JSC (KASE: CHFM). The Company develops, manufactures and supplies markets located in Kazakhstan and Central Asia with affordable and high quality medicinal products. The Company’s production capacity enables the annual manufacturing of 600 million tablets, 300 million ampoules, 6 million infusions, 40 million vials of antibiotics and 26 million vials of syrups. The company is the leader of the Kazakh pharmaceutical market with its portfolio that includes over 200 generic drugs which are used in 12 different therapeutic categories for treatment of diseases in various therapeutic fields. SANTO Company is the responsible employer for over 1000 employees in Shymkent and all regions of the Republic of Kazakhstan. The Company exports its products into countries such as Turkmenistan, Kyrgyzstan, Mongolia, Tajikistan, Russia, and Ukraine.

Tatiana Filipchik, PR-manager

SANTO Company

Address: 19 floor, block 5B, Nurly-Tau PFC, 17/1 Al Farabi Ave., Almaty 050013, Kazakhstan
Tel.: +7 (727) 3121833
e-mail: tatyana.filipchik@santo.kz
www.santo.kz